Compare GEL & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | BCRX |
|---|---|---|
| Founded | 1996 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 1996 | 1995 |
| Metric | GEL | BCRX |
|---|---|---|
| Price | $14.11 | $9.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $19.50 | ★ $20.82 |
| AVG Volume (30 Days) | 435.7K | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,912,770,000.00 | $25,186,000.00 |
| Revenue This Year | $12.12 | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $13.75 | $6.00 |
| 52 Week High | $18.64 | $10.94 |
| Indicator | GEL | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 67.47 |
| Support Level | N/A | $8.04 |
| Resistance Level | $16.38 | $10.04 |
| Average True Range (ATR) | 0.55 | 0.46 |
| MACD | -0.05 | 0.16 |
| Stochastic Oscillator | 15.07 | 63.20 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.